Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy

被引:5
作者
Moise, PA [1 ]
Schentag, JJ [1 ]
机构
[1] Millard Fillmore Hosp, Clin Pharmacokinet Lab, Buffalo, NY 14209 USA
关键词
D O I
10.1097/00001432-199812000-00005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Despite the advances in pharmacokinetic and pharmacodynamic modelling, there is still much more to gain from this concept. The use of pharmacokinetic and pharmacodynamic modelling in vitro, in animal and in human models has confirmed that an index, such as peak concentration divided by the minimum inhibitory concentration (C-max/MIC), the area under the curve divided by the minimum inhibitory concentration (AUC/MIC) and time above the minimum inhibitory concentration (T>(MIC)), may be used as an aid to understanding better the variability between patients who receive similar antibiotic dosage regimens but have dissimilar outcomes. Efforts to find the optimal pharmacokinetic or pharmacodynamic index predictive of response is crucial to identify targets that will ensure efficacy and for the prediction of failure. Curr Opin infect Dis 11:673-680. (C) 1998 Lippincott Williams & Wilkins.
引用
收藏
页码:673 / 680
页数:8
相关论文
共 42 条
[1]   POPULATION PHARMACOKINETIC METHODS TO OPTIMIZE ANTIBIOTIC EFFECTS [J].
AMSDEN, GW ;
BALLOW, CH ;
SCHENTAG, JJ .
DRUG INVESTIGATION, 1993, 5 (05) :256-268
[2]   ANALYSIS OF A NEW METHOD FOR ASSESSING ACTIVITY OF COMBINATIONS OF ANTIMICROBIALS - AREA UNDER THE BACTERICIDAL ACTIVITY CURVE [J].
BARRIERE, SL ;
ELY, E ;
KAPUSNIK, JE ;
GAMBERTOGLIO, JG .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1985, 16 (01) :49-59
[3]   Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect [J].
Boswell, FJ ;
Andrews, JM ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (02) :149-153
[4]   Experimental efficacy of combined ceftriaxone and amoxycillin on penicillin-resistant and broad-spectrum cephalosporin-resistant Streptococcus pneumoniae infection [J].
Chavanet, P ;
Dalle, F ;
Delisle, P ;
Duong, M ;
Pechinot, A ;
Buisson, M ;
D'Athis, P ;
Portier, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (02) :237-246
[5]   ENTEROBACTER BACTEREMIA - CLINICAL-FEATURES AND EMERGENCE OF ANTIBIOTIC-RESISTANCE DURING THERAPY [J].
CHOW, JW ;
FINE, MJ ;
SHLAES, DM ;
QUINN, JP ;
HOOPER, DC ;
JOHNSON, MP ;
RAMPHAL, R ;
WAGENER, MM ;
MIYASHIRO, DK ;
YU, VL .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (08) :585-590
[6]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[7]   PHARMACODYNAMICS OF AMIKACIN INVITRO AND IN MOUSE THIGH AND LUNG INFECTIONS [J].
CRAIG, WA ;
REDINGTON, J ;
EBERT, SC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :29-40
[8]  
DallaCosta T, 1997, INT J CLIN PHARM TH, V35, P426
[9]   Use of pharmacodynamic parameters to predict efficacy of combination therapy by using fractional inhibitory concentration kinetics [J].
den Hollander, JG ;
Mouton, JW ;
Verbrugh, HA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) :744-748
[10]   PHARMACODYNAMICS OF A FLUOROQUINOLONE ANTIMICROBIAL AGENT IN A NEUTROPENIC RAT MODEL OF PSEUDOMONAS SEPSIS [J].
DRUSANO, GL ;
JOHNSON, DE ;
ROSEN, M ;
STANDIFORD, HC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :483-490